+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Non-Cystic Fibrosis Bronchiectasis - Pipeline Insight, 2021

  • ID: 4989213
  • Clinical Trials
  • July 2021
  • Region: Global
  • 60 Pages
  • DelveInsight

FEATURED COMPANIES

  • Boehringer Ingelheim
  • CSL Behring
  • Insmed Incorporated
  • Novartis
  • SANTHERA PHARMACEUTICALS
This Non-Cystic Fibrosis Bronchiectasis - Pipeline Insight, 2021 provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Non-Cystic Fibrosis Bronchiectasis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

Non-Cystic Fibrosis Bronchiectasis Understanding


Non-Cystic Fibrosis Bronchiectasis: Overview


Non-cystic fibrosis (non-CF) bronchiectasis is a progressive respiratory disease characterized by a permanent dilation of bronchi, retention of mucus, and ciliary clearance impairment. Clinical features include chronic daily sputum, cough, shortness of breath, and recurrent respiratory infections, with consequent increased morbidity and worsened quality of life. One of the cornerstones in the management of bronchiectasis is the identification and treatment of underlying causes. The symptoms and clinical course of NCFB are variable. Some patients have no symptoms at all or symptoms only during exacerbations, whereas others have them daily. The classic clinical manifestations of this clinical condition are cough and daily mucopurulent sputum production, often lasting months to years. Blood-streaked sputum or hemoptysis may result from airway damage associated with acute infection. Dyspnea and wheezing occur in 75% of patients. Pleuritic chest pain occurs in 50% of patients and reflects the presence of distended peripheral airways or distal pneumonitis adjacent to a visceral pleural surface. Physical examination of the chest shows adventitious breath sounds, such as crackles (70%), wheezing (34%) or rhonchi (44%).

Non-Cystic Fibrosis Bronchiectasis - Pipeline Insight, 2021 report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Non-Cystic Fibrosis Bronchiectasis pipeline landscape is provided which includes the disease overview and Non-Cystic Fibrosis Bronchiectasis treatment guidelines. The assessment part of the report embraces, in depth Non-Cystic Fibrosis Bronchiectasis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Non-Cystic Fibrosis Bronchiectasis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights


The companies and academics are working to assess challenges and seek opportunities that could influence Non-Cystic Fibrosis Bronchiectasis R&D. The therapies under development are focused on novel approaches to treat/improve Non-Cystic Fibrosis Bronchiectasis.

Non-Cystic Fibrosis Bronchiectasis Emerging Drugs Chapters


This segment of the Non-Cystic Fibrosis Bronchiectasis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Non-Cystic Fibrosis Bronchiectasis Emerging Drugs


Brensocatib: Insmed Incorporated

Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1) being developed by Insmed for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases. DPP1 is an enzyme responsible for activating neutrophil serine proteases (NSPs), such as neutrophil elastase, in neutrophils when they are formed in the bone marrow. Neutrophils are the most common type of white blood cell and play an essential role in pathogen destruction and inflammatory mediation. In chronic inflammatory lung diseases, neutrophils accumulate in the airways and result in excessive active NSPs that cause lung destruction and inflammation. Brensocatib may decrease the damaging effects of inflammatory diseases such as bronchiectasis by inhibiting DPP1 and its activation of NSPs. Currently, it is in Phase III stage of clinical trial evaluation to treat Non-Cystic Fibrosis Bronchiectasis.

CSL787: CSL Behring

It is a human plasma-derived immunoglobulin for administration via a nebulizer for the potential prevention of chronic respiratory tract infections and progression of chronic lung disease.

Non-Cystic Fibrosis Bronchiectasis: Therapeutic Assessment


This segment of the report provides insights about the different Non-Cystic Fibrosis Bronchiectasis drugs segregated based on following parameters that define the scope of the report, such as:


Major Players in Non-Cystic Fibrosis Bronchiectasis


There are approx. 5+ key companies which are developing the therapies for Non-Cystic Fibrosis Bronchiectasis. The companies which have their Non-Cystic Fibrosis Bronchiectasis drug candidates in the most advanced stage, i.e. phase III include, Insmed Incorporated.

Phases


This report covers around 5+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

Non-Cystic Fibrosis Bronchiectasis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Inhalation
  • Subcutaneous
  • Topical.
  • Molecule Type

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Non-Cystic Fibrosis Bronchiectasis: Pipeline Development Activities


The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Non-Cystic Fibrosis Bronchiectasis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities


The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Non-Cystic Fibrosis Bronchiectasis drugs.

Non-Cystic Fibrosis Bronchiectasis Report Insights

  • Non-Cystic Fibrosis Bronchiectasis Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Non-Cystic Fibrosis Bronchiectasis Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions Answered


Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Non-Cystic Fibrosis Bronchiectasis drugs?
  • How many Non-Cystic Fibrosis Bronchiectasis drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Non-Cystic Fibrosis Bronchiectasis?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Non-Cystic Fibrosis Bronchiectasis therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Non-Cystic Fibrosis Bronchiectasis and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • Insmed Incorporated
  • CSL Behring
  • Boehringer Ingelheim
  • Novartis
  • SANTHERA PHARMACEUTICALS

Key Products

  • Brensocatib
  • CSL787
  • BI 1323495
  • Tobramycin inhalation powder
  • Lonodelestat
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Boehringer Ingelheim
  • CSL Behring
  • Insmed Incorporated
  • Novartis
  • SANTHERA PHARMACEUTICALS

IntroductionExecutive Summary
Non-Cystic Fibrosis Bronchiectasis: Overview
  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics
  • Comparative Analysis

Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Late Stage Products (Phase III)
  • Comparative Analysis

Brensocatib: Insmed Incorporated
  • Product Description
  • Research and Development
  • Product Development Activities

Mid Stage Products (Phase II)
  • Comparative Analysis

Tobramycin inhalation powder: Novartis
  • Product Description
  • Research and Development
  • Product Development Activities

Early Stage Products (Phase I)
  • Comparative Analysis

CSL787: CSL Behring
  • Product Description
  • Research and Development
  • Product Development Activities

Inactive Products
  • Comparative Analysis

Non-Cystic Fibrosis Bronchiectasis Key CompaniesNon-Cystic Fibrosis Bronchiectasis Key ProductsNon-Cystic Fibrosis Bronchiectasis- Unmet NeedsNon-Cystic Fibrosis Bronchiectasis- Market Drivers and BarriersNon-Cystic Fibrosis Bronchiectasis- Future Perspectives and ConclusionNon-Cystic Fibrosis Bronchiectasis Analyst ViewsNon-Cystic Fibrosis Bronchiectasis Key CompaniesAppendix
List of Tables
Table 1 Total Products for Non-Cystic Fibrosis Bronchiectasis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
List of Figures
Figure 1 Total Products for Non-Cystic Fibrosis Bronchiectasis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Insmed Incorporated
  • CSL Behring
  • Boehringer Ingelheim
  • Novartis
  • SANTHERA PHARMACEUTICALS
Note: Product cover images may vary from those shown